An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis

Trial Profile

An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use
  • Acronyms MEASURE 1 ext
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 17 Jun 2017 Three year results from phase 3 extension trial MEASURE 1 presented at the 18th Annual Congress of the European League Against Rheumatism
    • 15 May 2017 Results assessing the efficacy and safety of secukinumab in patients with active ankylosing spondylitis over 3 years, published in the Clinical and Experimental Rheumatology
    • 10 Nov 2015 Results published in a Novartis Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top